Immuneering Corporation (IMRX)
NASDAQ: IMRX · Real-Time Price · USD
1.940
+0.080 (4.28%)
Nov 5, 2024, 11:17 AM EST - Market open
Company Description
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients.
Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.
Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
Immuneering Corporation
| Country | United States |
| Founded | 2008 |
| IPO Date | Jul 30, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 68 |
| CEO | Benjamin Zeskind |
Contact Details
Address: 245 Main Street, Second Floor Cambridge, Massachusetts 02142 United States | |
| Phone | 617 500 8080 |
| Website | immuneering.com |
Stock Details
| Ticker Symbol | IMRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 0001790340 |
| CUSIP Number | 45254E107 |
| ISIN Number | US45254E1073 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Benjamin J. Zeskind M.B.A., Ph.D. | Co-Founder, President, Chief Executive Officer and Director |
| Robert J. Carpenter M.B.A., M.S. | Co-Founder and Chair Emeritus |
| Dr. Brett M. Hall Ph.D. | Chief Scientific Officer |
| Harold E. Brakewood | Chief Business Officer |
| Mallory Morales CPA | Principal Financial and Accounting Officer, Chief Accounting Officer and Treasurer |
| Paula George CPA | Director of Accounting and Operations and Assistant Corporate Controller |
| Michael D. Bookman J.D. | Chief Legal Officer and Secretary |
| Leah R. Neufeld | Chief People Officer |
| Dr. Peter King Ph.D. | Head of Discovery and Vice President |
| Dr. Praveen Nair Ph.D. | Head of Translational Pharmacology and Vice President |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 2, 2024 | 8-K/A | [Amend] Current report |
| Sep 12, 2024 | 8-K | Current Report |
| Aug 6, 2024 | 10-Q | Quarterly Report |
| Aug 6, 2024 | 8-K | Current Report |
| Jun 13, 2024 | 8-K | Current Report |
| May 23, 2024 | 8-K | Current Report |
| May 7, 2024 | 10-Q | Quarterly Report |
| May 7, 2024 | 8-K | Current Report |
| Apr 23, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 23, 2024 | DEF 14A | Other definitive proxy statements |